Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $53.40

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received an average recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $53.50.

Several research analysts have weighed in on the stock. Oppenheimer increased their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, September 27th. Morgan Stanley boosted their target price on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Leerink Partners restated an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Monday, September 9th. Guggenheim lifted their price objective on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets began coverage on Kymera Therapeutics in a research note on Friday. They set a “market perform” rating and a $55.00 target price on the stock.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of KYMR. Franklin Resources Inc. raised its position in Kymera Therapeutics by 35.1% during the 3rd quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock worth $1,356,000 after buying an additional 7,647 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Kymera Therapeutics by 7.2% during the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after acquiring an additional 308,954 shares during the period. Quarry LP purchased a new position in Kymera Therapeutics during the third quarter worth about $95,000. HighTower Advisors LLC acquired a new stake in Kymera Therapeutics in the third quarter valued at about $494,000. Finally, HighVista Strategies LLC purchased a new stake in Kymera Therapeutics in the 3rd quarter valued at approximately $603,000.

Kymera Therapeutics Trading Up 5.9 %

Shares of KYMR stock opened at $46.67 on Wednesday. Kymera Therapeutics has a twelve month low of $21.20 and a twelve month high of $53.27. The company’s 50-day moving average price is $46.44 and its 200-day moving average price is $42.47. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of -20.06 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.90) EPS. As a group, equities research analysts predict that Kymera Therapeutics will post -2.79 EPS for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.